BR112018076633A2 - mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿uk - Google Patents
mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿ukInfo
- Publication number
- BR112018076633A2 BR112018076633A2 BR112018076633-0A BR112018076633A BR112018076633A2 BR 112018076633 A2 BR112018076633 A2 BR 112018076633A2 BR 112018076633 A BR112018076633 A BR 112018076633A BR 112018076633 A2 BR112018076633 A2 BR 112018076633A2
- Authority
- BR
- Brazil
- Prior art keywords
- asfv
- swine fever
- georgia
- fever virus
- mutant
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 241000701386 African swine fever virus Species 0.000 title abstract 3
- 241000282887 Suidae Species 0.000 title abstract 3
- 241000710777 Classical swine fever virus Species 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 229940124590 live attenuated vaccine Drugs 0.000 title 1
- 229940023012 live-attenuated vaccine Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 208000007407 African swine fever Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12061—Methods of inactivation or attenuation
- C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12071—Demonstrated in vivo effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
o vírus de febre suína africana (asfv) é o agente etiológico de uma doença viral contagiosa frequentemente letal de porcos domésticos. o controle da febre suína africana é dificultado pela não disponibilidade de vacinas. as vacinas experimentais têm sido derivadas de asfvs vivos atenuados de ocorrência natural, adaptados a cultura de células ou geneticamente modificados; entretanto, essas vacinas são somente bem sucedidas para proteger contra vírus homólogos. nós construímos um vírus ¿9gl/¿uk recombinante derivado do isolado georgia 2007 (asfv-g) de asfv altamente virulento por deleção dos genes específicos 9gl (b119l) e o uk (dp96r) associados a virulência. in vivo, o asfv-g ¿9gl/¿uk, administrado de forma intramuscular a suínos, mesmo em doses relativamente elevadas (106 had50) não induz doença. substancialmente, os animais infectados com 104 ou 106 had50 ficam fortemente protegidos contra o a exposição à doença clínica quando desafiados 28 dias após infecção com a cepa gerogia 2007 parental virulenta.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/200,407 | 2016-07-01 | ||
| US15/200,407 US9808520B1 (en) | 2016-07-01 | 2016-07-01 | Rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate |
| PCT/US2017/039277 WO2018005358A1 (en) | 2016-07-01 | 2017-06-26 | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018076633A2 true BR112018076633A2 (pt) | 2019-04-24 |
Family
ID=60189680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018076633-0A BR112018076633A2 (pt) | 2016-07-01 | 2017-06-26 | mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿uk |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9808520B1 (pt) |
| EP (1) | EP3478705B1 (pt) |
| JP (1) | JP7121950B2 (pt) |
| KR (1) | KR102443074B1 (pt) |
| CN (1) | CN109952310B (pt) |
| AU (1) | AU2017288932B2 (pt) |
| BR (1) | BR112018076633A2 (pt) |
| CA (1) | CA3029552A1 (pt) |
| CL (1) | CL2018003769A1 (pt) |
| DK (1) | DK3478705T3 (pt) |
| EA (1) | EA201990085A1 (pt) |
| ES (1) | ES2971606T3 (pt) |
| FI (1) | FI3478705T3 (pt) |
| GE (1) | GEP20207186B (pt) |
| HR (1) | HRP20240254T1 (pt) |
| HU (1) | HUE065240T2 (pt) |
| LT (1) | LT3478705T (pt) |
| MX (1) | MX2019000048A (pt) |
| MY (1) | MY197376A (pt) |
| PH (1) | PH12018502684A1 (pt) |
| PL (1) | PL3478705T3 (pt) |
| PT (1) | PT3478705T (pt) |
| RS (1) | RS65124B1 (pt) |
| SG (1) | SG11201811370XA (pt) |
| SI (1) | SI3478705T1 (pt) |
| UA (1) | UA125584C2 (pt) |
| WO (1) | WO2018005358A1 (pt) |
| ZA (1) | ZA201900259B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017128039A1 (zh) * | 2016-01-26 | 2017-08-03 | 浙江大学 | 基因组合及其用途 |
| CN110302371B (zh) * | 2019-08-21 | 2023-05-26 | 军事科学院军事医学研究院军事兽医研究所 | 灭活asfv作为复合疫苗的免疫攻毒保护成分的用途 |
| US11007263B2 (en) | 2019-09-24 | 2021-05-18 | The United States Of America, As Represented By The Secretary Of Agriculture | Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L |
| JP7382628B2 (ja) * | 2019-10-11 | 2023-11-17 | 国立研究開発法人農業・食品産業技術総合研究機構 | アフリカ豚コレラウイルスの製造方法及び検出方法 |
| CN110760617B (zh) * | 2019-11-26 | 2021-12-21 | 华中农业大学 | 检测非洲猪瘟病毒野毒的实时荧光pcr引物探针组合及试剂盒 |
| KR20210087810A (ko) | 2020-01-03 | 2021-07-13 | 주식회사 중앙백신연구소 | 신규한 아프리카돼지열병의 예방 및 치료를 위한 바이러스 백신조성물 |
| CN111925994B (zh) * | 2020-07-03 | 2023-05-26 | 中国农业科学院兰州兽医研究所 | 一种dp71l基因缺失的重组非洲猪瘟病毒及其制备方法和应用 |
| CN111748563A (zh) * | 2020-07-10 | 2020-10-09 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟基因缺失弱毒株的构建及其作为疫苗的应用 |
| CN112063592A (zh) * | 2020-07-10 | 2020-12-11 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用 |
| CN111996175B (zh) * | 2020-09-04 | 2023-11-21 | 军事科学院军事医学研究院军事兽医研究所 | 缺失e66l、i267l基因的非洲猪瘟减毒及活疫苗 |
| WO2022107793A1 (ja) * | 2020-11-20 | 2022-05-27 | 国立研究開発法人農業・食品産業技術総合研究機構 | 不死化豚胎子小腸マクロファージ |
| US20240053340A1 (en) | 2020-12-24 | 2024-02-15 | Intervet Inc. | African swine fever diva immunoassay |
| CN112852761B (zh) * | 2021-03-08 | 2022-08-23 | 中国农业科学院兰州兽医研究所 | 基因缺失减毒非洲猪瘟病毒株的构建及作为疫苗的应用 |
| CN114392345B (zh) * | 2021-03-11 | 2023-08-25 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | E199l蛋白在促进细胞凋亡中的用途及方法 |
| CN113061588B (zh) * | 2021-05-20 | 2023-08-01 | 军事科学院军事医学研究院军事兽医研究所 | 缺失i226r基因的非洲猪瘟病毒减毒株及其活疫苗 |
| US11801296B2 (en) * | 2021-06-30 | 2023-10-31 | The United States Of America, As Represented By The Secretary Of Agriculture | Development of a novel live attenuated African swine fever vaccine based in the deletion of gene A137R |
| CN114107228B (zh) * | 2021-11-11 | 2023-06-13 | 中国农业科学院兰州兽医研究所 | 缺失十二个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用 |
| CN113831394B (zh) * | 2021-11-29 | 2022-04-12 | 中国人民解放军军事科学院军事医学研究院 | 一种非洲猪瘟病毒asfv基因的重组病毒组合及由其制备的疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8610106D0 (en) * | 1986-04-25 | 1986-05-29 | Central Blood Lab Authority | Human igm-producing heterohybridoma |
| US8846055B2 (en) * | 2006-05-30 | 2014-09-30 | The United States Of America, As Represented By The Secretary Of Agriculture | Virulence determinant within the E2 structural glycoprotein of classical swine fever virus |
| US9352032B2 (en) * | 2014-03-07 | 2016-05-31 | The United States Of America As Represented By The Secretary Of Agriculture | Live attenuated antigenically marked classical swine fever vaccine |
| GB201410971D0 (en) * | 2014-06-19 | 2014-08-06 | Pirbright Inst The | Vaccine |
| US9463234B2 (en) * | 2014-09-24 | 2016-10-11 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated african swine fever virus strain induces protection against challenge with homologous virulent parental virus georgia 2007 isolate |
| US9528094B2 (en) * | 2014-11-10 | 2016-12-27 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated African swine fever virus vaccine based in the deletion of MGF genes |
-
2016
- 2016-07-01 US US15/200,407 patent/US9808520B1/en active Active
-
2017
- 2017-06-26 CA CA3029552A patent/CA3029552A1/en active Pending
- 2017-06-26 CN CN201780053651.9A patent/CN109952310B/zh active Active
- 2017-06-26 WO PCT/US2017/039277 patent/WO2018005358A1/en unknown
- 2017-06-26 ES ES17821008T patent/ES2971606T3/es active Active
- 2017-06-26 KR KR1020197003279A patent/KR102443074B1/ko active IP Right Grant
- 2017-06-26 FI FIEP17821008.4T patent/FI3478705T3/fi active
- 2017-06-26 BR BR112018076633-0A patent/BR112018076633A2/pt unknown
- 2017-06-26 PL PL17821008.4T patent/PL3478705T3/pl unknown
- 2017-06-26 HR HRP20240254TT patent/HRP20240254T1/hr unknown
- 2017-06-26 EP EP17821008.4A patent/EP3478705B1/en active Active
- 2017-06-26 GE GEAP201714984A patent/GEP20207186B/en unknown
- 2017-06-26 JP JP2018568233A patent/JP7121950B2/ja active Active
- 2017-06-26 AU AU2017288932A patent/AU2017288932B2/en active Active
- 2017-06-26 HU HUE17821008A patent/HUE065240T2/hu unknown
- 2017-06-26 MY MYPI2018002721A patent/MY197376A/en unknown
- 2017-06-26 EA EA201990085A patent/EA201990085A1/ru unknown
- 2017-06-26 LT LTEPPCT/US2017/039277T patent/LT3478705T/lt unknown
- 2017-06-26 MX MX2019000048A patent/MX2019000048A/es unknown
- 2017-06-26 SG SG11201811370XA patent/SG11201811370XA/en unknown
- 2017-06-26 UA UAA201900970A patent/UA125584C2/uk unknown
- 2017-06-26 SI SI201731488T patent/SI3478705T1/sl unknown
- 2017-06-26 DK DK17821008.4T patent/DK3478705T3/da active
- 2017-06-26 RS RS20240124A patent/RS65124B1/sr unknown
- 2017-06-26 PT PT178210084T patent/PT3478705T/pt unknown
-
2018
- 2018-12-19 PH PH12018502684A patent/PH12018502684A1/en unknown
- 2018-12-21 CL CL2018003769A patent/CL2018003769A1/es unknown
-
2019
- 2019-01-15 ZA ZA2019/00259A patent/ZA201900259B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018076633A2 (pt) | mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿uk | |
| JP2014520117A5 (pt) | ||
| RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| BRPI0821286A8 (pt) | Métodos e composições para imunizar porcos contra circovirus suino | |
| BR112012021650A2 (pt) | "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina." | |
| JP2017502662A5 (pt) | ||
| BR112015017966A2 (pt) | composições imunogênicas compreendendo vírus silificado e métodos de uso | |
| FI3244920T3 (fi) | Suu- ja sorkkatautirokote | |
| Liu et al. | Development of recombinant goatpox virus expressing Echinococcus granulosus EG95 vaccine antigen | |
| Calvo-Pinilla et al. | Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48 h before, or 48 h after challenge | |
| Moreno et al. | Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge | |
| US20170021009A1 (en) | Heat Inactivated Poxvirus Improves Vaccination Results | |
| Reina et al. | Vaccines against monkeypox | |
| Phelps et al. | Comparative efficacy of intramuscular and scarification routes of administration of live smallpox vaccine in a murine challenge model | |
| BR112017013270A2 (pt) | ?composição de vacina contra vírus da dengue, métodos para induzir uma resposta imune contra dengue, para reduzir a probabilidade de infecção por dengue, ou prevenir ou atenuar os sintomas da mesma, e, uso de uma composição de vacina contra vírus da dengue?. | |
| Vasconcelos et al. | Are booster doses of yellow fever vaccine needed? | |
| Jang et al. | Baculoviral COVID-19 Delta DNA vaccine cross-protects against SARS-CoV2 variants in K18-ACE2 transgenic mice | |
| Li et al. | Recombinant canine adenovirus type-2 expressing TgROP16 provides partial protection against acute Toxoplasma gondii infection in mice | |
| Kim et al. | Stability and efficacy of the 3′-UTR A4G-G5A variant of viral hemorrhagic septicemia virus (VHSV) as a live attenuated immersion VHSV vaccine in olive flounder (Paralichthys olivaceus) | |
| Danon et al. | Use of the LC16m8 smallpox vaccine in immunocompromised individuals is still too risky | |
| BR112022007474A2 (pt) | Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma | |
| Chang et al. | A single dose of Astragalus saponins adjuvanted inactivated vaccine for pseudorabies virus protected mice against lethal challenge | |
| BR112014023398A2 (pt) | vírus da doença de marek modidicado e vacinas feitas do mesmo | |
| Borca | ASF Vaccine Development and Research |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |